TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6692582

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (AG) after hypophysectomy
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (AG) after adrenalectomy
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (AG)
Number of subjects: 9
Study: 30810332

Group type: EXPERIMENTAL
Intervention: NAFLD patients (120 patients)
Number of subjects: 403
Study: 30024798

Group type: EXPERIMENTAL
Intervention: 6-month intervention including food, diabetes education, health care referral, and glucose monitoring
Number of subjects: 568

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 568
Study: 26930341

Group type: EXPERIMENTAL
Intervention: Silicone Suture Plate (SSP) device
Number of subjects: 8

Group type: COMPARATOR
Intervention: Standard suturing techniques
Number of subjects: 8
Study: 24650002

Group type: EXPERIMENTAL
Intervention: ICP monitoring
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 22697441

Group type: EXPERIMENTAL
Intervention: False safety behavior elimination therapy (F-SET)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 96
Study: 20102889

Group type: EXPERIMENTAL
Intervention: Grayscale IVUS attenuated plaques
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: VH-TCFA (thin-capped fibroatheromas)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: VH-ThFA (thick-capped fibroatheromas)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Pathologic intimal thickening
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control sites (remaining 65 vessels)
Number of subjects: 64
Study: 18568502

Group type: EXPERIMENTAL
Intervention: Intranasal microemulsion treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15821951

Group type: EXPERIMENTAL
Intervention: LY544344 (80 mg bid for 1 week)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11830461

Group type: EXPERIMENTAL
Intervention: Foscarnet (60 mg/kg for 2 weeks, then 90 mg/kg for 2 weeks if needed)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Ganciclovir (5 mg/kg every 12 hours for 2 weeks, then 6 mg/kg once daily for 5 days per week if needed)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Foscarnet and Ganciclovir
Number of subjects: 213
Study: 12212053

Group type: EXPERIMENTAL
Intervention: Captopril (along with antibiotics and oxygen) for 14 days
Number of subjects: 36

Group type: COMPARATOR
Intervention: Antibiotics and oxygen
Number of subjects: 36
Study: 7542965

Group type: EXPERIMENTAL
Intervention: Laser prostatectomy using Prolase-II fiber at 40 W for 90 s
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 2202461

Group type: EXPERIMENTAL
Intervention: Cyclosporine, 1 mg/kg daily from days 1-28 administered intravenously in four patients and orally in five.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 9
Study: 6988169

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 1 g cephradine administered twice daily for 1 week
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 1 g cephradine administered 4-times a day
Number of subjects: 104

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 104
Study: 31511629

Group type: EXPERIMENTAL
Intervention: sEMG-B intervention (12 sessions)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional physiotherapy (12 weeks, 24 sessions)
Number of subjects: 40
Study: 28502596

Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium Histolyticum (CCH)
Number of subjects: 1493
Study: 25819531

Group type: EXPERIMENTAL
Intervention: Insulin Glargine (IG)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Neutral Protamine Hagedorn (NPH) insulin
Number of subjects: 66
Study: 23706362

Group type: EXPERIMENTAL
Intervention: Weight loss treatment
Number of subjects: 113
Study: 21362084

Group type: EXPERIMENTAL
Intervention: SNaP(®) Wound Care System
Number of subjects: 65

Group type: COMPARATOR
Intervention: VAC(®) Therapy System
Number of subjects: 65
Study: 18955102

Group type: EXPERIMENTAL
Intervention: DHA (220 mg/day)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: DHA+AA (220 mg/day each)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 17484791

Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional mechanical ventilation
Number of subjects: 0
Study: 15028313

Group type: EXPERIMENTAL
Intervention: D1 gastrectomy
Number of subjects: 162

Group type: COMPARATOR
Intervention: D2 gastrectomy
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 162
Study: 11213243

Group type: EXPERIMENTAL
Intervention: Transhiatal esophagectomy
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Videofluoroscopic assessment of swallowing
Number of subjects: 10
Study: 10050456

Group type: EXPERIMENTAL
Intervention: Peroral pulse therapy with methylprednisolone, 1000 mg daily for three days
Number of subjects: 28

Group type: COMPARATOR
Intervention: Intravenous pulse therapy with methylprednisolone, 1000 mg daily for three days
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Peroral pulse therapy with methylprednisolone
Number of subjects: 28
Study: 8065284

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 100 mg tablet, twice daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Flurbiprofen mouthwash 10 ml (0.25%), rinsed 6 times daily for three minutes
Number of subjects: 40
Study: 3385024

Group type: EXPERIMENTAL
Intervention: 2% minoxidil gel
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 2% minoxidil solution
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 29450903

Group type: EXPERIMENTAL
Intervention: Increased physical education (PE) from 60 to 200 minutes per week
Number of subjects: 304

Group type: COMPARATOR
Intervention: Standard physical education (PE) of 60 minutes per week
Number of subjects: 304
Study: 26768926

Group type: EXPERIMENTAL
Intervention: Proseal laryngeal mask airway insertion
Number of subjects: 100

Group type: COMPARATOR
Intervention: Tracheal intubation
Number of subjects: 100
Study: 25470803

Group type: EXPERIMENTAL
Intervention: Caffeine (3mg*kg‐1)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 22993340

Group type: EXPERIMENTAL
Intervention: Exemestane therapy for 30 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tamoxifen followed by exemestane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Analgesics use
Number of subjects: 0
Study: 19818953

Group type: EXPERIMENTAL
Intervention: W‐CBT (cognitive‐behavioural worry intervention)
Number of subjects: 24

Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 24
Study: 17715042

Group type: EXPERIMENTAL
Intervention: Azithromycin tablet (500 mg) from pharmaceutical company 1
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Azithromycin tablet (500 mg) from pharmaceutical company 2
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Azithromycin tablet (500 mg) from pharmaceutical company 3
Number of subjects: 18
Study: 16246409

Group type: EXPERIMENTAL
Intervention: Pimozide (n=6)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Paroxetine (n=5)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 11
Study: 10940175

Group type: EXPERIMENTAL
Intervention: Azithromycin (3-day course)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Amoxycillin/clavulanate (2-week course)
Number of subjects: 42
Study: 9265992

Group type: EXPERIMENTAL
Intervention: Patch testing
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Cow's milk challenge
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Skin prick test
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Patch test
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Polysensitization
Number of subjects: 113
Study: 8334031

Group type: EXPERIMENTAL
Intervention: Clodronate 400 mg daily for 30 days, followed by 60 days of no treatment (Group 2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral calcitriol 2 mcg for 5 days and clodronate 400 mg daily for additional 25 days, followed by 60 days of no treatment (Group 3)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No treatment (Group 1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clodronate (Group 2)
Number of subjects: 60
Study: 3568691

Group type: EXPERIMENTAL
Intervention: Biostatistical Monitoring Committee
Number of subjects: 0
Study: 3348152

Group type: EXPERIMENTAL
Intervention: 1.3 kcal/min Realmentyl
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 3.3 kcal/min Realmentyl
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control solution
Number of subjects: 10
Study: 31352663

Group type: EXPERIMENTAL
Intervention: Nutraceutical compounds (red yeast rice, Berberine, Coenzyme Q10, folic acid and chrome) added to diet for 3 months
Number of subjects: 131

Group type: COMPARATOR
Intervention: Diet only
Number of subjects: 131
Study: 28790226

Group type: EXPERIMENTAL
Intervention: Metformin (3 x 500 mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 25999334

Group type: EXPERIMENTAL
Intervention: Transference-focused psychotherapy (TFP)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Treatment by experienced community therapists
Number of subjects: 104
Study: 24261946

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with a grass pollen tablet for 4 months
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 82
Study: 22150686

Group type: EXPERIMENTAL
Intervention: Leukoreduction filtration performed at designated intervals post-collection after storage in transport shippers for at least 2 hours.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Storage times ranged from 28 to 458 minutes before leukoreduction filtration.
Number of subjects: 50
Study: 19528806

Group type: EXPERIMENTAL
Intervention: Acute autologous blood transfusion with acute normovolemic haemodilution (group A)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Homologous blood transfusion (group H)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups (A and H)
Number of subjects: 62
Study: 16741259

Group type: EXPERIMENTAL
Intervention: Partial body potassium (PBK) measurement system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Computed tomography and magnetic resonance imaging
Number of subjects: 0
Study: 15252704

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 11716371

Group type: EXPERIMENTAL
Intervention: Fixed-bearing total knee prosthesis (AMK)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Mobile-bearing total knee prosthesis (LCS)
Number of subjects: 116
Study: 9143001

Group type: EXPERIMENTAL
Intervention: Intranasal CRH (20 micrograms every 10 min)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Intranasal CRH
Number of subjects: 11
Study: 7802851

Group type: EXPERIMENTAL
Intervention: Alprazolam (5 mg daily)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 3314832

Group type: EXPERIMENTAL
Intervention: Colchicine (mean dose 6.7 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31954014

Group type: EXPERIMENTAL
Intervention: Dual task training (Group A)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional physiotherapy (Group B)
Number of subjects: 64
Study: 31004420

Group type: EXPERIMENTAL
Intervention: PSV SIGH
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: NAVA
Number of subjects: 14

Group type: COMPARATOR
Intervention: PSV
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: PSV SIGH and NAVA
Number of subjects: 14
Study: 29211727

Group type: EXPERIMENTAL
Intervention: 3D-platform video game training (Super Mario 64) for 6 months
Number of subjects: 33

Group type: COMPARATOR
Intervention: Active control (self-directed computerized music lessons)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 3D-platform video game training (Super Mario 64)
Number of subjects: 33

Group type: COMPARATOR
Intervention: No intervention (no-contact control group)
Number of subjects: 33
Study: 26593888

Group type: EXPERIMENTAL
Intervention: Educational program provided by a nurse
Number of subjects: 96

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 96
Study: 23480324

Group type: EXPERIMENTAL
Intervention: Aripiprazole (10 or 30 mg/day)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study: 21950194

Group type: EXPERIMENTAL
Intervention: Warfarin adjusted to maintain INR between 1.5 and 1.9 (Group A)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Warfarin adjusted to maintain INR between 2 and 3 (Group B)
Number of subjects: 39
Study: 18422823

Group type: EXPERIMENTAL
Intervention: Smoking cessation support offered by letter and referral to NHS stop smoking services
Number of subjects: 6856
Study: 16939033

Group type: EXPERIMENTAL
Intervention: Ammonium hexafluorosilicate (SiF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diamine silver fluoride (AgF)
Number of subjects: 0
Study: 14575972

Group type: EXPERIMENTAL
Intervention: Gliclazide
Number of subjects: 36

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 36
Study: 10959618

Group type: EXPERIMENTAL
Intervention: Active absorbable algal calcium (AAA Ca)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Calcium carbonate (CaCO3)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Non‐calcium‐containing placebo (C)
Number of subjects: 9
Study: 9495931

Group type: EXPERIMENTAL
Intervention: Absorbable collagen membrane in guided tissue regeneration (GTR) therapy
Number of subjects: 12

Group type: COMPARATOR
Intervention: Surgical flap debridement only (Control)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Unoperated control sites
Number of subjects: 12
Study: 8454791

Group type: EXPERIMENTAL
Intervention: Skin testing with major and minor determinants of benzylpenicillin and minor determinant mixtures of ampicillin, amoxicillin, or cloxacillin
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Skin testing with semisynthetic penicillin reagents derived from ampicillin, amoxicillin, or cloxacillin
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Ampicillin and amoxicillin
Number of subjects: 112

Group type: COMPARATOR
Intervention: Benzylpenicillin derivatives
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 112

Group type: COMPARATOR
Intervention: Benzylpenicillin
Number of subjects: 112
Study: 3755683

Group type: EXPERIMENTAL
Intervention: 200 mg cimetidine with 1 g sucralfate
Number of subjects: 12

Group type: COMPARATOR
Intervention: 200 mg cimetidine with water
Number of subjects: 12
Study: 29388909

Group type: EXPERIMENTAL
Intervention: Automated messaging reminders
Number of subjects: 95

Group type: COMPARATOR
Intervention: No automated messaging reminders (Control)
Number of subjects: 95
Study: 27575713

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 110

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 110
Study: 24342386

Group type: EXPERIMENTAL
Intervention: ABMT + CBT
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: ABMT placebo + CBT
Number of subjects: 63

Group type: COMPARATOR
Intervention: CBT-alone
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Active ABMT
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 63
Study: 22797552

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Fenoterol
Number of subjects: 132

Group type: COMPARATOR
Intervention: Nifedipine and Fenoterol
Number of subjects: 132
Study: 20211022

Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m2 on day 1 of a 21-day cycle) plus best supportive care (BSC)
Number of subjects: 900

Group type: COMPARATOR
Intervention: Placebo plus best supportive care (BSC)
Number of subjects: 900
Study: 17372737

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (2.5 mg)
Number of subjects: 40
Study: 16376755

Group type: EXPERIMENTAL
Intervention: H/D amount less than 2 kg (group 1)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: H/D amount between 2 and 3 kg (group 2)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: H/D amount larger than 3 kg (group 3)
Number of subjects: 81
Study: 12421100

Group type: EXPERIMENTAL
Intervention: Statins (simvastatin, pravastatin, fluvastatin, lovastatin)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 19
Study: 9797791

Group type: EXPERIMENTAL
Intervention: Ritonavir (200 mg every 8 hours)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg every 12 hours)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ritonavir and clarithromycin in combination
Number of subjects: 22
Study: 8044016

Group type: EXPERIMENTAL
Intervention: TCM‐WM therapy (oral administration and external treatment of TCM plus wet-compressing with antibiotics)
Number of subjects: 34

Group type: COMPARATOR
Intervention: WM therapy (Western medicine therapy including pain-killer, antibiotics, debridement and dressing change)
Number of subjects: 34
Study: 2698935

Group type: EXPERIMENTAL
Intervention: Intensive dietary advice
Number of subjects: 141

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 141
Study: 1090718

Group type: EXPERIMENTAL
Intervention: Intraperitoneal cephaloridine (25 mg/kg every 6 hr for 48 hr)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Systemic injection of cephaloridine
Number of subjects: 69
Study: 31208499

Group type: EXPERIMENTAL
Intervention: Early short-term upgrade therapy (ICS/LABA inhaled every morning for 7-10 days)
Number of subjects: 100
Study: 27761000

Group type: EXPERIMENTAL
Intervention: T80/A5/H12.5 (telmisartan 80 mg/amlodipine 5 mg plus hydrochlorothiazide 12.5 mg)
Number of subjects: 309

Group type: COMPARATOR
Intervention: T80/A5 (telmisartan 80 mg/amlodipine 5 mg)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: T80/A5/H12.5
Number of subjects: 309

Group type: COMPARATOR
Intervention: T80/A5
Number of subjects: 309
Study: 27005658

Group type: EXPERIMENTAL
Intervention: Resveratrol supplementation (75 mg twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25226015

Group type: COMPARATOR
Intervention: Tavaborole 2.5%
Number of subjects: 336

Group type: COMPARATOR
Intervention: Tavaborole 5.0%
Number of subjects: 336

Group type: COMPARATOR
Intervention: Tavaborole 7.5%
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Tavaborole 5.0% (cohort 3 of study 2)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Tavaborole 2.5%, 5.0%, and 7.5%
Number of subjects: 336
Study: 21916994

Group type: EXPERIMENTAL
Intervention: Double-guidewire (DG) technique
Number of subjects: 44

Group type: COMPARATOR
Intervention: Precut sphincterotomy (PS) technique
Number of subjects: 44
Study: 20808251

Group type: COMPARATOR
Intervention: Fentanyl (1 μg/kg bolus)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Remifentanil (0.5 μg/kg bolus)
Number of subjects: 42
Study: 17295579

Group type: EXPERIMENTAL
Intervention: Multidimensional treatment foster care (MTFC)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Group care
Number of subjects: 81
Study: 16228834

Group type: EXPERIMENTAL
Intervention: Choice condition (patients could choose to watch the video)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Watching the video (intervention)
Number of subjects: 166

Group type: COMPARATOR
Intervention: No choice condition (patients had no choice to watch the video)
Number of subjects: 166
Study: 11901038

Group type: EXPERIMENTAL
Intervention: Ad5‐FGF4
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 10215753

Group type: EXPERIMENTAL
Intervention: Alniditan 2 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Alniditan 4 mg
Number of subjects: 27
Study: 7838899

Group type: EXPERIMENTAL
Intervention: Clonidine (Clon), 150 micrograms IV
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 12
Study: 1900396

Group type: EXPERIMENTAL
Intervention: Desflurane with O2 (n = 6)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Desflurane with O2 and 60% N2O (n = 6)
Number of subjects: 12
Study: 6339289

Group type: EXPERIMENTAL
Intervention: Halometasone ointment (0.05%)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Fluocortolone + fluocortolone caproate ointment (0.25% each)
Number of subjects: 182
Study: 31696724

Group type: EXPERIMENTAL
Intervention: Fully Covered Self-Expandable Biliary Metal Stents (FCSEBMS) placed prophylactically in 15 patients
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Fully Covered Self-Expandable Biliary Metal Stents (FCSEBMS) placed for treatment of refractory bleed in 7 patients
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Fully Covered Self-Expandable Biliary Metal Stents (FCSEBMS)
Number of subjects: 22
Study: 30106880

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (200 mg/d)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 27169685

Group type: EXPERIMENTAL
Intervention: Alphacalcidol 1 μg daily for 6 months
Number of subjects: 178

Group type: COMPARATOR
Intervention: Cholecalciferol 1 000 IU daily for 6 months
Number of subjects: 178
Study: 26431365

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) during visual scanning training
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sham TENS during visual scanning training
Number of subjects: 29
Study: 23359516

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Faldaprevir 120 mg QD with lead-in (LI)
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Faldaprevir 240 mg QD with lead-in (LI)
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Faldaprevir 240 mg QD
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Faldaprevir 240 mg QD in mRVR patients
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Faldaprevir 240 mg QD in GT-1a patients
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Faldaprevir 120 mg QD/LI
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Faldaprevir 240 mg QD/LI
Number of subjects: 429
Study: 22586900

Group type: EXPERIMENTAL
Intervention: Ergoferon
Number of subjects: 0